Background. Cryptococcus gattii (Cg) has caused increasing infections in the US Pacific Northwest (PNW) since 2004. We describe this outbreak and compare clinical aspects of infection in the United States among patients infected with different Cg genotypes.
Since 2004, human Cryptococcus gattii (Cg) infections have been increasingly reported in the Pacific Northwest (PNW) region of the United States, with most cases being reported in human immunodeficiency virus (HIV)-uninfected patients from Washington and Oregon [1, 2] . These reports have followed the occurrence of an outbreak of Cg infection in British Columbia (BC), Canada, that has been ongoing since 1999 [3] and that is considered to be the likely source of the US outbreak [2, 4] . In North America, the outbreak of Cg infection has been associated with significant morbidity and high rates of mortality among those infected [1, 3] . Although many ideas have been postulated regarding the source of and reasons for the outbreak [5] , to date, these remain unclear.
Cg is a genetically diverse organism that can be subdivided into at least 4 different molecular types: VGI, VGII, VGIII, and VGIV [6] . The outbreak of Cg infection in North America has largely comprised 3 clonal genetic subtypes of VGII, designated VGIIa, VGIIb, and VGIIc [7] [8] [9] , first reported in association with the outbreak [1, 3, 7, 9] ; to date, VGIIc has not been reported outside the United States. Infections with other, nonclonal VGII subtypes as well as VGI, VGIII, and VGIV have been reported previously from outside North America, frequently from otherwise healthy patients who develop severe central nervous system (CNS) disease as a result of their infection [10] [11] [12] [13] [14] [15] [16] [17] . Rare reports of historic Cg infections in the United States also exist, primarily VGI-and VGIII-type infections from southern California [11, 18, 19, 20] .
The Centers for Disease Control and Prevention (CDC), in conjunction with state and local health department partners, began coordinating Cg surveillance in the United States in 2009. We report the epidemiology and clinical characteristics of human Cg infections in the United States and discuss the possible influence of Cg molecular types and patient immune status on clinical presentation and disease course.
MATERIALS AND METHODS

Surveillance
Surveillance for Cg was passive and laboratory-based and began in PNW states during 2004-2005, when cases first began occurring. A case was defined as culture-confirmed Cg infection in a resident of the United States with illness onset on or after 1 January 2004. During 2004-2009, PNW cryptococcal isolates were sent to the BC Centre for Disease Control (BCCDC) for confirmation as Cg.
Beginning in 2009, all isolates, including those previously identified at BCCDC, were submitted to the CDC. State and local health departments performed medical record reviews for patients with laboratory-confirmed Cg infection using standardized case report forms, which included questions about demographic characteristics, illness onset, signs and symptoms of infection, clinical findings, and patient outcome. Case report forms were forwarded to the CDC, which began coordinating national surveillance in October 2009; thus, chart reviews for cases occurring before October 2009 were done retrospectively.
As awareness of the outbreak expanded, cases were also reported and isolates were submitted to the CDC from other states, most commonly from a clinician aware of the PNW outbreak. In these states, both treating clinicians and state health departments assisted in completing and submitting patient case report forms. One isolate (from North Carolina) was kindly provided to the CDC by Dr Joseph Heitman (Duke University) several years after the patient's illness.
Complete demographic and clinical data were not available for all patients. Cases described in this report include all previously published infections associated with the US outbreak [1, 2, 21, 22] .
Case-patient infections were defined as likely acquired in the PNW or BC if the patient resided in Washington or Oregon or resided in other states but reported a residential or travel history to Washington, Oregon, or BC during the year before illness onset. Infections in case patients residing outside the PNW who did not report residence in or travel to Washington or Oregon in the previous year were defined as not acquired in the PNW or BC.
A preexisting condition was defined as the use of oral corticosteroids during the year before illness onset; HIV infection; existing lung, renal, liver, or heart disease; blood cancers, diabetes, connective tissue disorders, or rheumatic conditions at the time of illness onset; a history of a solid organ or hematopoietic stem cell transplantation; or being a smoker at illness onset. Immunocompromising conditions were considered to be only solid organ or stem cell transplantations, connective tissue disorders, rheumatic conditions, past-year oral corticosteroid use, or HIV infection.
Laboratory Analysis
Isolates were sent to the CDC for species confirmation and genotyping. Cg was confirmed by culture using canavanine-glycinebromothymol blue agar [23] ; Cg genotype was identified by multilocus sequence typing of the genetic loci URA5, IGS1, LAC1, CAP59, GPD1, PLB1, and SOD1, as described elsewhere [24, 25] .
Data Analysis
Case-patient demographic characteristics, travel history, clinical signs, symptoms, underlying conditions at presentation, and outcome were compared among patients with differing genotypes of infection. We compared genotype of Cg infection, clinical characteristics, and outcome between patients with and patients without any preexisting condition and between patients with immunocompromising conditions and all other patients. We also evaluated factors associated with death among patients with Cg infection by univariate and multivariate analysis.
Data were analyzed using SAS software, version 9.2 (SAS Institute). Relative risks and P values were calculated using the v 2 or Fisher exact tests, when appropriate. The Wilcoxon ranksum test was used to compare continuous variables. Logistic regression was used to calculate odds ratios in multivariate analysis. In the multivariate model selection process, models were explored using all variables that were significant in univariate analysis; variables that remained statistically significantly associated with death or had borderline statistical significance were included in the final model. The Hosmer-Lemeshow goodness-of-fit test was used to evaluate the fit of final model. VGIIa/b/c isolates (nonoutbreak-strain infections), 11 were VGI, 6 were VGIII, and 1 was of a subtype belonging to the VGII genotype, but not an outbreak strain (Table 1) .
Eighty-one case patients (84%) resided in Washington or Oregon; of these, 33 reported travel history, 8 (24%) of whom reported travel at least once during the prior year to areas of BC or Vancouver Island where Cg infection is endemic. All 81 patients were considered likely to have acquired their infections in the PNW or BC. Of the 15 case patients residing outside Washington or Oregon, 2 (from Idaho and Alaska) reported extensive travel to both Washington and Oregon during the year before illness onset (Table 1) ; these infections were considered to have likely been acquired in the PNW. Of the 83 total case patients with likely Cg acquisition in the PNW or BC, 78 (94%) had outbreak-strain infections, compared with none (0%) of the 13 case patients with Cg acquisition outside the PNW or BC (P , .0001; Table 2 ).
Case Patients
Illness onset ranged from December 2004 through June 2011 ( Figure 1 ). The number of cases reported from Washington and Oregon increased each year; increasing numbers of cases were also reported from outside these states in 2009, 2010, and early 2011.
Demographic data were available for 76 case patients (79%). The median age was 54 years (range, 2-95 years); 43 (54%) were male. Overall, the most common presenting symptoms were headache (61%), nausea (48%), cough (48%), weight loss (47%), and dyspnea (45%) ( Table 3 ). Fifty-four percent of patients had documented pneumonia; 49% had meningitis. Fifty-two patients (76%) had a preexisting condition (Table 3) .
Clinical presentation differed by the infecting genotype of Cg. Case patients with outbreak-strain infections were more likely than those with nonoutbreak-strain infections to present with symptoms consistent with respiratory disease, including cough (P 5 .007) or dyspnea (P 5 .03; Table 3 ). In contrast, certain clinical signs consistent with elevated intracranial pressure, including headache (P 5 .04), blurry vision (P 5 .01), or seizure (P 5 .01), were more frequent among case patients with nonoutbreak-strain infections. Overall, 75% of case patients with outbreak-strain infections had any documented respiratory symptom, compared with 36% of patients with nonoutbreakstrain infections (P 5 .03), whereas 90% of patients with nonoutbreak-strain infections had any documented CNS symptoms, compared with 37% of patients with outbreak-strain infections (P 5 .008; Table 3 ).
The presence of any preexisting condition was more frequent among case patients with outbreak-strain infections (86%) than among patients with nonoutbreak-strain infections (31%; P , .0001); immunocompromising conditions were also more frequent among case patients with outbreak-strain infections, although this difference was not statistically significant (P 5 .06; Table 3 ). No single preexisting condition, except a history of cancer (P 5 .05), differed in frequency by Cg genotype. Current smoking was the only reported preexisting condition for 5 patients; 4 had outbreak-strain infections. The presence of any preexisting condition was positively associated with pneumonia, dyspnea, or any respiratory symptom at presentation and negatively associated with male sex, meningitis, and CNS symptoms at presentation ( Table 4 ). All other presentation symptoms, frequency of hospitalization or death, and the presence of cryptococcomas were not different between patients with and those without without a preexisting condition (data not shown). When comparing characteristics of case patients with VGIIa, VGIIb, and VGIIc infections, case patients with VGIIb infection were more likely than those with VGIIa infection to be male (5 of 5 vs 19 of 42; P 5 .05), and case patients with VGIIa infection were more likely than those with VGIIb infection to present with nausea (16 of 27 vs 0 of 5; P 5 .04). Other patient and clinical characteristics, including patient outcome, did not differ among case patients with VGIIa, VGIIb, or VGIIc infections (data not shown).
Patient Outcomes
Ninety-one percent of patients were hospitalized, and 19 patients (33%) died of Cg infection, a median of 59 days after illness onset. In univariate analyses, age $50 years, diabetes, liver disease, and a history of oral steroid use increased the risk of death (all P # .01; Table 4 ). The presence of any CNS symptom at presentation was associated in univariate analyses with a decreased risk of death (P 5 .003). Risk of death was not different between patients with and without pneumonia, meningitis, any (all) preexisting conditions, or any (all) immunocompromising conditions (Table 4) .
In a multivariate model that included the presence of any CNS symptom at presentation, age $50 years, and past-year oral steroid use, oral steroid use remained positively associated with death (P 5 .048) and CNS symptoms remained negatively associated with death (P 5 .035). The final model provided an adequate fit for the data (goodness-of-fit test, P 5 .85; Table 4 ).
DISCUSSION
We describe an outbreak caused by the emerging pathogen Cryptococcus gattii, with most cases occurring in Washington and Oregon. With the exception of a single Cg isolate reported during the early 1970s from Seattle [26] , infections associated with this outbreak [2, 21, 22, 24, 27, 28] are the only published human Cg infections from these states. We found that Cg-infected patients detected in our surveillance were most frequently aged 30-69 years; were infected with Cg genotypes VGIIa, VGIIb, or VGIIc; and had underlying preexisting conditions that might have predisposed them to infection. However, we also found that infections caused by other genotypes of Cg are occurring, probably less frequently, in states outside Washington and Oregon. Cg infections in the United States are associated with a high mortality rate, regardless of Cg genotype or the presence of a preexisting condition in the patient.
Of importance, we found that different genotypes of Cg are associated with different clinical profiles during infection. Patients with outbreak-strain infections, most of whom resided in Washington or Oregon, more commonly presented with respiratory than CNS symptoms; in fact, 63% of patients with outbreak-strain infections had no symptoms specific to CNS infection. In contrast, all but 1 patient with nonoutbreak-strain infections, most of whom resided outside Washington or Oregon, had CNS symptoms, whereas only a minority had respiratory symptoms. The more frequent respiratory findings among patients with outbreak-strain infections are important: Cg infection should be considered in patients with serious respiratory illness and recent exposure to the PNW.
In contrast to the relative infrequency of preexisting conditions among patients with nonoutbreak-strain infections, we found that the vast majority of patients with outbreak-strain infections had preexisting conditions. In addition, patients with outbreak-strain infections were significantly older than patients with nonoutbreak-strain infections, which may also reflect comparatively more immunosuppression among patients with outbreak-strain infections. Thus, the clinical profile of patients with nonoutbreak-strain infections in the United States-CNS disease primarily in otherwise healthy patients-appears to be similar to that reported for many patients with nonoutbreakstrain Cg infections outside North America [10, 12, 14, [29] [30] [31] .
Although we identified few Cg-infected case patients infected with HIV, the proportion of HIV infection among all Cg cases was substantially above the population average (0.6%) [32] , suggesting that, although it is uncommon as a risk factor, HIV infection may increase the risk of developing clinical Cg infection in the United States. These findings are similar to previous reports from BC [3] and contradict the common perception that Cg infection is exclusively a disease of otherwise healthy individuals.
Case patients had high morbidity and mortality related to Cg infection, with 91% of patients requiring hospitalization and a case-fatality rate of 33%. In addition, we found that a history of oral steroid use was associated with increased odds of death in all patients. Of interest, having a CNS symptom at presentation was strongly associated with decreased risk of death. This might be attributable to the lower frequency of preexisting conditions among patients exhibiting CNS symptoms, compared with patients without CNS symptoms. Alternately, earlier recognition of disease may be occurring among patients with CNS symptoms, resulting in earlier and improved treatment. However, our sample size was small, and future studies addressing factors associated with patient death will be critical to providing data to support optimal patient care.
Infections with nonoutbreak-strain Cg have never been reported to occur in a clonally expanding, outbreak pattern. Similarly, nonoutbreak-strain Cg in the United States does not appear to be clonally expanding, and these sporadic infections should be considered independently-although not with less concern-from the ongoing outbreak in the PNW. Of note, Cg has been reported previously in the United States, mostly from southern California [11, 18, 33] ; a recent study of 30 human Cg isolates collected from southern and central California during the early 1990s showed that 28 were VGIII, 3 were VGI, and 1 was VGII [20] , similar to the genotypic profile of Cg isolates that we found in states outside the PNW. These data suggest that VGI and VGIII Cg infections now being observed in California may be representative of long-standing Cg endemicity in the state. In addition, sporadic Cg infections have, rarely, occurred in patients from states outside the PNW in the past [11, 19, 33] . It is unclear whether the infections now being reported from other states are attributable to enhanced awareness and surveillance or whether they represent an unrecognized public health problem in these regions. Continued awareness and surveillance of these infections is important to determine the burden of nonoutbreakstrain infections, particularly outside the PNW. In contrast, the clonal expansion of outbreak strains of Cg represents a novel health concern in North America. With existing data, it is challenging to predict the extent of the future geographic or human spread for these outbreak strains. Improved and continued surveillance and collection of clinical data on these infections will be critical to understanding the precise nature of the differences between these and the nonoutbreakstrain infections in the United States.
Our data have several limitations. First, we had limited numbers of nonoutbreak-strain infections, and thus, some epidemiologic associations might be obscured or, conversely, overrepresented. Second, as noted above, our data are based on the early functioning of a new surveillance system and probably overrepresent severe infections, whereas less severe infections may be going unnoticed or unreported. In addition, because not all clinical laboratories determine Cryptococcus identity to the species level (and many infections are diagnosed using antigen testing alone), species gattii infections are likely presumed to be due to Cryptococcus neoformans at least some of the time and are therefore not identified by surveillance. Third, multivariate analysis was limited because of small sample size and collinearity among some of the variables examined. Fourth, our data on treatment were incomplete and did not permit analysis of patient outcomes by treatment type. Finally, because of differential levels of clinician awareness of and reporting practices for Cg between the PNW and other states, reporting of Cg infections from states outside the PNW is not comparable to reporting in the PNW, and thus, the conclusions that can be made from comparisons among infections of different Cg genotypes might be limited.
In summary, we describe an ongoing outbreak of Cg infection in the United States with substantial associated morbidity and mortality. Because of this high mortality, consideration of Cg infection in patients with respiratory symptoms with or without coexisting meningitis, particularly among persons with exposure to the PNW, is warranted. Clinicians in all areas of the United States should be aware of this newly emerging pathogen and the diversity of clinical signs and symptoms that can occur with Cg infection.
Notes
